REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that Panome Bio has joined its COE Program. Panome Bio is a metabolomics and proteomics services company that provides biopharma innovators unparalleled access to the biomolecules closest to phenotype using its proprietary Next Generation Metabolomics™ technology.

REDWOOD CITY，CA，2023年11月1日（GLOBE NEWSWIRE）-Seer Inc.（纳斯达克股票代码：Seer），一家生命科学公司，将蛋白质组学的颠覆性新平台商业化，今天宣布Panome Bio已加入其COE计划。Panome Bio是一家代谢组学和蛋白质组学服务公司，为生物制药创新者提供使用其专有的下一代代谢组学无与伦比的最接近表型的生物分子™ 技术。

Panome Bio joins Seer’s global COE network of leading service providers, who are all committed to accelerating the adoption of unbiased, deep proteomics at scale. Seer COEs have been selected for their demonstrated expertise in proteomics, their ability to deliver the highest quality service, and their commitment to partnering to expand the ecosystem around deep, unbiased proteomics using Seer’s technology.

Panome Bio加入了Seer全球COE领先服务提供商网络，他们都致力于加速大规模采用无偏见的深度蛋白质组学。Seer-COEs因其在蛋白质组学方面的专业知识，提供最高质量服务的能力以及他们致力于合作，利用Seer技术扩展围绕深层无偏见蛋白质组学的生态系统而被选中。

Seer’s COE network makes it easier for customers around the world to access the value of the Proteograph Product Suite and the new Proteograph XT Assay. “At Seer, we are passionate about empowering more researchers to access deep, unbiased proteomics so that we can really begin to fundamentally understand biology in a functional and dynamic way,” said Omid Farokhzad, CEO and Founder of Seer.

Seer的COE网络使世界各地的客户更容易访问Proteograph产品套件和新的Proteograph XT分析的价值。Seer首席执行官兼创始人Omid Farokhzad说：“在Seer，我们热衷于授权更多研究人员访问深度，无偏见的蛋白质组学，以便我们真正能够以功能和动态的方式从根本上理解生物学。

“We have been impressed with Panome Bio’s approach to serving biopharma, from their focus on understanding the customer’s goals, to their approach to data analysis, to reports that go beyond a list of data points. We see them as an ideal partner in making it easier for the scientific community to accelerate its insights into biology and disease with peptide-level proteomic data, complemented by metabolomic data.

“我们对Panome Bio服务生物制药的方法印象深刻，从专注于理解客户的目标，到他们的数据分析方法，到超越数据点列表的报告。我们认为它们是一个理想的合作伙伴，使科学界更容易通过肽水平蛋白质组学数据加速其对生物学和疾病的见解，补充d通过代谢组学数据。

We are thrilled to be partnering with a leading multi-omics provider like Panome Bio to help realize this potential.” Panome Bio’s .

我们很高兴能与Panome Bio等领先的多组学提供商合作，帮助实现这一潜力。”Panome Bio's。